Published in J Neurosci on June 04, 2008
A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers. Nat Struct Mol Biol (2015) 2.53
Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J (2009) 1.73
IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol (2010) 1.55
BRI2 protein regulates β-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE). J Biol Chem (2011) 1.47
microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain. J Neurosci (2015) 1.45
BRI2 inhibits amyloid beta-peptide precursor protein processing by interfering with the docking of secretases to the substrate. J Neurosci (2008) 1.42
5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. Ann Neurol (2012) 1.31
Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains. Alzheimers Res Ther (2012) 1.22
Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice. Mol Neurodegener (2012) 1.22
Modeling familial Danish dementia in mice supports the concept of the amyloid hypothesis of Alzheimer's disease. Proc Natl Acad Sci U S A (2010) 1.21
Maturation of BRI2 generates a specific inhibitor that reduces APP processing at the plasma membrane and in endocytic vesicles. Neurobiol Aging (2009) 1.19
Memory deficits due to familial British dementia BRI2 mutation are caused by loss of BRI2 function rather than amyloidosis. J Neurosci (2010) 1.14
Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol (2012) 1.14
Danish dementia mice suggest that loss of function and not the amyloid cascade causes synaptic plasticity and memory deficits. Proc Natl Acad Sci U S A (2010) 1.13
Generation and initial characterization of FDD knock in mice. PLoS One (2009) 1.13
Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo. Mol Neurodegener (2011) 1.10
Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo. Eur J Neurosci (2013) 1.04
Conformational templating of α-synuclein aggregates in neuronal-glial cultures. Mol Neurodegener (2013) 1.01
BRI3 inhibits amyloid precursor protein processing in a mechanistically distinct manner from its homologue dementia gene BRI2. J Biol Chem (2009) 0.99
Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol Neurodegener (2011) 0.99
AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice. Mol Ther (2009) 0.98
Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener (2012) 0.97
BRICHOS domains efficiently delay fibrillation of amyloid β-peptide. J Biol Chem (2012) 0.97
Cerebral amyloidosis: amyloid subunits, mutants and phenotypes. Cell Mol Life Sci (2009) 0.96
Sequential activation of Snail1 and N-Myc modulates sonic hedgehog-induced transformation of neural cells. Cancer Res (2011) 0.92
Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis. Mol Neurodegener (2012) 0.92
The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence. Biol Psychiatry (2013) 0.87
Specific Chaperones and Regulatory Domains in Control of Amyloid Formation. J Biol Chem (2015) 0.86
Memory deficits of British dementia knock-in mice are prevented by Aβ-precursor protein haploinsufficiency. J Neurosci (2012) 0.83
Animal models of human amyloidoses: are transgenic mice worth the time and trouble? FEBS Lett (2009) 0.82
Amyloid peptides ABri and ADan show differential neurotoxicity in transgenic Drosophila models of familial British and Danish dementia. Mol Neurodegener (2014) 0.81
Viral expression of ALS-linked ubiquilin-2 mutants causes inclusion pathology and behavioral deficits in mice. Mol Neurodegener (2015) 0.80
Amelogenins: Multi-Functional Enamel Matrix Proteins and Their Binding Partners. J Oral Biosci (2011) 0.80
Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis. Mult Scler Int (2011) 0.79
Holdase activity of secreted Hsp70 masks amyloid-β42 neurotoxicity in Drosophila. Proc Natl Acad Sci U S A (2016) 0.79
Oxidative stress and mitochondria-mediated cell death mechanisms triggered by the familial Danish dementia ADan amyloid. Neurobiol Dis (2015) 0.78
Anti-Aβ single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer's disease. Hum Mol Genet (2015) 0.78
The effect of brief neonatal cryoanesthesia on physical development and adult cognitive function in mice. Behav Brain Res (2013) 0.77
Murine Aβ over-production produces diffuse and compact Alzheimer-type amyloid deposits. Acta Neuropathol Commun (2015) 0.77
Differences in memory development among C57BL/6NCrl, 129S2/SvPasCrl, and FVB/NCrl mice after delay and trace fear conditioning. Comp Med (2014) 0.77
Generalised Anxiety Disorder--A Twin Study of Genetic Architecture, Genome-Wide Association and Differential Gene Expression. PLoS One (2015) 0.77
BRI2 interacts with BACE1 and regulates its cellular levels by promoting its degradation and reducing its mRNA levels. Curr Alzheimer Res (2013) 0.76
CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S DISEASE. Hirosaki Igaku (2010) 0.76
A Common Phenotype Polymorphism in Mammalian Brains Defined by Concomitant Production of Prolactin and Growth Hormone. PLoS One (2016) 0.75
Tetracapsuloides bryosalmonae infection affects the expression of genes involved in cellular signal transduction and iron metabolism in the kidney of the brown trout Salmo trutta. Parasitol Res (2015) 0.75
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem (2001) 4.51
Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron (2005) 3.72
Abeta40 inhibits amyloid deposition in vivo. J Neurosci (2007) 2.47
A stop-codon mutation in the BRI gene associated with familial British dementia. Nature (1999) 2.46
Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience (2006) 2.19
A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci U S A (2000) 2.11
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 1.96
Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry (2006) 1.88
The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. J Biol Chem (2005) 1.67
BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer. Trends Biochem Sci (2002) 1.66
Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia. Nat Neurosci (1999) 1.53
BRI2 interacts with amyloid precursor protein (APP) and regulates amyloid beta (Abeta) production. J Biol Chem (2005) 1.48
Regulated intramembrane proteolysis of Bri2 (Itm2b) by ADAM10 and SPPL2a/SPPL2b. J Biol Chem (2007) 1.46
Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem (2006) 1.42
Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging (2001) 1.39
Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest (2003) 1.19
Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan AND A{beta}) in the absence of compact plaques. J Biol Chem (2005) 1.18
Axonal transport of British and Danish amyloid peptides via secretory vesicles. FASEB J (2003) 1.17
Expression of BRI, the normal precursor of the amyloid protein of familial British dementia, in human brain. Acta Neuropathol (2003) 1.10
Genetic alterations of the BRI2 gene: familial British and Danish dementias. Brain Pathol (2006) 1.09
Amyloid-beta protofibrils differ from amyloid-beta aggregates induced in dilute hexafluoroisopropanol in stability and morphology. J Biol Chem (2004) 1.03
Beta-amyloid protein converting enzyme 1 and brain-specific type II membrane protein BRI3: binding partners processed by furin. J Neurochem (2005) 1.02
Structural role of glycine in amyloid fibrils formed from transmembrane alpha-helices. Biochemistry (2005) 1.00
Secondary structure and interfacial aggregation of amyloid-beta(1-40) on sodium dodecyl sulfate micelles. Biochemistry (2006) 0.97
Beta-amyloid protein oligomers induced by metal ions and acid pH are distinct from those generated by slow spontaneous ageing at neutral pH. Eur J Biochem (2003) 0.96
Sequence, genomic structure and tissue expression of Human BRI3, a member of the BRI gene family. Gene (2001) 0.95
Structure and neurotoxicity of novel amyloids derived from the BRI gene. Biochem Soc Trans (2005) 0.83
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 11.59
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord (2006) 8.04
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet (2003) 5.92
Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA (2011) 5.21
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet (2006) 4.80
The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2002) 4.27
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet (2009) 4.00
Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med (2005) 4.00
Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2009) 3.65
Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci (2007) 3.52
NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest (2003) 3.50
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Substrate-targeting gamma-secretase modulators. Nature (2008) 3.38
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol (2004) 3.37
Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol (2007) 3.25
Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA (2002) 3.16
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet (2004) 3.12
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A (2005) 2.95
BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron (2004) 2.90
Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat Immunol (2005) 2.81
Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76
Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation (2009) 2.73
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord (2002) 2.56
Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci (2007) 2.55
Abeta40 inhibits amyloid deposition in vivo. J Neurosci (2007) 2.47
Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain (2009) 2.45
Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med (2005) 2.43
Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem (2003) 2.31
Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood (2008) 2.24
Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet (2012) 2.23
Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron (2003) 2.17
Notch1 augments NF-kappaB activity by facilitating its nuclear retention. EMBO J (2005) 2.16
Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis (2002) 2.14
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet (2005) 2.08
Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci (2005) 2.03
Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther (2005) 2.02
Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol (2010) 2.02
A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A (2002) 1.97
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 1.96
Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2004) 1.92
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci (2003) 1.87
Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci (2011) 1.86
TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener (2013) 1.83
Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest (2007) 1.80
Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain (2009) 1.77
Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol (2005) 1.77
Suppression of hippocampal TRPM7 protein prevents delayed neuronal death in brain ischemia. Nat Neurosci (2009) 1.75
TCR-mediated Notch signaling regulates proliferation and IFN-gamma production in peripheral T cells. J Immunol (2003) 1.75
Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J (2009) 1.73
Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol (2002) 1.70
Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. Blood (2008) 1.69
Notch signaling is activated by TLR stimulation and regulates macrophage functions. Eur J Immunol (2008) 1.68
Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol (2010) 1.66
Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene (2005) 1.63
Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet (2011) 1.60
Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis (2009) 1.60
Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol (2011) 1.59
A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One (2011) 1.55
IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol (2010) 1.55
Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Hum Mol Genet (2003) 1.55
Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J Neurosci (2013) 1.54
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science (2013) 1.50
De novo truncating FUS gene mutation as a cause of sporadic amyotrophic lateral sclerosis. Hum Mutat (2010) 1.49
Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci U S A (2002) 1.48
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci (2007) 1.48
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Alzheimer's disease presenting as corticobasal syndrome. Mov Disord (2006) 1.46
Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study: implication of additional loci. Arch Neurol (2008) 1.44
Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. Curr Alzheimer Res (2006) 1.44